• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Adv Exp Med Biol . The Primary Outcomes and Epidemiological and Clinical Features of Coronavirus Disease 2019 (COVID-19) in Iran

tetano

Editor, Senior Moderator
Adv Exp Med Biol


. 2021;1321:199-210.
doi: 10.1007/978-3-030-59261-5_17.
The Primary Outcomes and Epidemiological and Clinical Features of Coronavirus Disease 2019 (COVID-19) in Iran


Amir Vahedian-Azimi[SUP] 1 [/SUP], Sara Ashtari[SUP] 2 [/SUP], Gholamhosein Alishiri[SUP] 3 [/SUP], Alireza Shahriary[SUP] 3 [/SUP], Mohsen Saberi[SUP] 4 [/SUP], Farshid Rahimi-Bashar[SUP] 5 [/SUP], Yunes Panahi[SUP] 6 [/SUP], Hossein Samadinia[SUP] 7 [/SUP], Mojtaba Ferdosi[SUP] 8 [/SUP], Iman Jafari[SUP] 1 [/SUP], Ensieh Vahedi[SUP] 3 [/SUP], Ali Ghazvini[SUP] 3 [/SUP], Mohamad Nikpouraghdam[SUP] 9 [/SUP], Keivan Goharimoghadam[SUP] 10 [/SUP], Morteza Izadi[SUP] 11 [/SUP], Nematollah Jonaidi-Jafari[SUP] 11 [/SUP], Sajad Shojaee[SUP] 12 [/SUP], Hamid Asadzadeh Aghdaei[SUP] 2 [/SUP], Mohamad Amin Pourhoseingholi[SUP] 13 [/SUP], Amirhossein Sahebkar[SUP] 14 15 16 17 [/SUP]



Affiliations

Abstract

Aim: We aimed to describe the epidemiological and clinical characteristics of Iranian patients with COVID-19.
Methods: In this single-center and retrospective study, patients with confirmed COVID-19 infections were enrolled. Univariate and multivariate logistic regression methods were used to explore the risk factors associated with outcomes.
Results: Of 179 patients with confirmed COVID-19 infection, 12 remained hospitalized at the end of the study and 167 were included in the final analysis. Of these, 153 (91.6%) were discharged and 14 (8.38%) died in hospital. Approximately half (50.9%) of patients suffered from a comorbidity, with diabetes or coronary heart disease being the most common in 20 patients. The most common symptoms on admission were fever, dyspnea, and cough. The mean durations from first symptoms to hospital admission was 8.64 ? 4.14 days, whereas the mean hospitalization time to discharge or death was 5.19 ? 2.42 and 4.35 ? 2.70 days, respectively. There was a significantly higher age in non-survivor patients compared with survivor patients. Multivariate regression showed increasing odds ratio (OR) of in-hospital death associated with respiratory rates >20 breaths/min (OR: 5.14, 95% CI: 1.19-22.15, p = 0.028) and blood urea nitrogen (BUN) >19 mg/dL (OR: 4.54, 95% CI: 1.30-15.85, p = 0.017) on admission. In addition, higher respiratory rate was associated with continuous fever (OR: 4.08, 95% CI: 1.18-14.08, p = 0.026) and other clinical symptoms (OR: 3.52, 95% CI: 1.05-11.87, p = 0.04).
Conclusion: The potential risk factors including high respiratory rate and BUN levels could help to identify COVID-19 patients with poor prognosis at an early stage in the Iranian population.

Keywords: Blood urea nitrogen; COVID-19; Iran; MERS; Respiratory rate; SARS.
 
Back
Top Bottom